Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including the results of Eli Lilly's ...

Mobility Mojo has announced a business update revealing how it is solving one of the biggest challenges organisations face, especially those operating in ...

Ely Lilly’s announcement to invest $6 billion into a manufacturing plant opened up a partnership with the University of ...

Once construction is complete in 2032, the company plans on creating some of its "biggest medicines" at the new facility.

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...